778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma

Autor: Gino K In, James Larkin, Yazan Samhouri, Marcus Butler, Victoria Atkinson, Jeffrey Chou, Juan Martin-Liberal, Patrick Terheyden, Sajeve Thomas, Wen Shi, Xiao Wu, Andrew S Poklepovic, Young Hong, Giri Sulur, Friedrich Graf Finckenstein, John B Haanen, Andrew JS Furness, Philip Lammers, Ryan H Nguyen, Idit Peretz
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Druh dokumentu: article
ISSN: 2051-1426
DOI: 10.1136/jitc-2023-SITC2023.0778
Databáze: Directory of Open Access Journals